Walid Mehanna, the chief data and A.I. officer at Merck KGaA, is spearheading the integration of artificial intelligence within the historic pharmaceutical company, aiming to enhance productivity and innovation across its extensive operations.
Under Mehanna's leadership, Merck KGaA is implementing a structured A.I. strategy likened to building a pyramid. The foundational layer focuses on everyday A.I. tools for personal productivity, while the middle layer aims to embed A.I. into critical workflows such as research and supply chain management. The pinnacle of this strategy is product A.I., which will enhance drug discovery processes. Mehanna emphasizes that the true transformation lies in the alignment of strategy, culture, and leadership rather than merely technological advancements.
Merck KGaA has also made significant strides with its internal A.I. platform, MyGPT, initially developed in-house but later enhanced through a partnership with the Berlin-based startup LangDock. This collaboration allows for GDPR compliance and flexibility in accessing various A.I. models without vendor lock-in. Additionally, a focus on governance has been integrated into their A.I. strategy, ensuring ethical considerations are addressed through a Digital Ethics Advisory Panel that evaluates potential risks and safeguards.
As Mehanna reflects on the evolving landscape of A.I., he notes that the competitive advantage now lies not solely in the models themselves but in the organizational context, data handling, and trust cultivated with stakeholders. He believes that A.I. will not eliminate jobs but rather transform them, necessitating leaders to adapt to a hybrid workforce of humans and A.I. agents. This perspective underscores the importance of being adaptable and useful in a rapidly changing industrial environment.